ClinicalTrials.gg
Enrolling by invitationNCT07493434Updated Mar 25, 2026

Evaluation of Pain Thresholds in Migraine Patients After Inhalation of Essential Oils: a Randomized Clinical Trial

An interventional study of Lavander essential oil and Peppermint essential oil in Migraine, sponsored by University of Sao Paulo. Enrolling by invitation at 1 site in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2025, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Migraine Disorders with a site in Brazil — 3 open to participants now, 4 under way, none of them phase 3. Migraine Disorders · Brazil.

Planned enrollment
4th of 23
200 · median 60
Started
2025
the only one that year
No phase
11 of 25
2 open now
Registered
25th of 25
by date
Lead sponsor
3 of 25
University of Sao Paulo

Among the 25 studies in Migraine Disorders with a site in Brazil, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 11 with no phase, and was the 25th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

3 of the 25 studies in Migraine Disorders with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Migraine Disorders with a site in Brazil, or all of them as a file.
02

Study summary

This study will test whether inhaling essential oils can change how sensitive people with migraine are to pressure pain. Participants will be allocated to inhale lavender, peppermint, a combination of both, or a control solution (distilled water with coconut oil). Each group will have 50 participants. The inhalation will last 15 minutes and will happen only once. Before and after the inhalation, we will measure how much pressure on certain areas of the head.

Read the detailed description

This is a parallel, randomized, placebo-controlled clinical trial to evaluate pain thresholds before and after the inhalation of essential oils or a control, in patients of both genders diagnosed with migraine. There will be three experimental groups, each with 50 participants (lavender, peppermint, and a combination of lavender and peppermint) and one control group with 50 participants (distilled water with coconut oil). The intervention will be conducted in a single session lasting 15 minutes, and participants will be evaluated before and immediately after the inhalation of the essential oils or control by measuring their pain thresholds in the following cephalic regions: occipital, masseter, temporal, vertex, and frontal. The randomization sequence will be generated by a statistician using the R software. The resulting randomization list will be stored in a sealed envelope and handled by an assistant evaluator who will not take part in the intervention. Participants will be allocated according to the random sequence based on their order of arrival.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • migraine
  • pain pressure threshold
  • volatile oils
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years
  • Diagnosis of episodic or chronic migraine according to the Internactional Classification of Headache Disorders (ICDH-3)
  • History of migraine for at least 1 year
  • Ability to understand and provide
  • Participants currently using or not using migraine preventive medication

Exclusion criteria

Exclusion Criteria:

  • Severe acute circulatory disorders
  • Diabetes melitus
  • Uncontrolled arterial hypertension
  • Fribromyagia
  • Anosmia or hyposmia
  • Known allergy or to essential oils or their components
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Lavander essential oil

    Participants inhale lavander essential oil (Lavandula angustifolia) administered via inhalation for 15 minutes during the experimental session

    Other: Lavander essential oil

  • Placebo comparator
    Control (Coconut oil and distilled water)

    Participants inhale a control solution consisting of coconut oil and distilled water, administered via inhalation for 15 minutes during the experimental session

    Other: Coconut oil

  • Experimental
    Peppermint essential oil

    Participants inhale peppermint essential oil (Mentha piperita) administered via inhalation for 15 minutes during the experimental session

    Other: Peppermint essential oil

  • Experimental
    Peppemint and lavander essential oil

    Participants inhale a combination of peppermint (Mentha piperita) an lavander (Lavandula angustifolia) essential oils administered via inhalation for 15 minutes during the experimental session

    Other: Lavandula angustifolia and Mentha Piperita

Interventions

  • OtherLavander essential oil

    Lavander essential oil (Lavandula angustifolia) administered by inhalation. Six drops are applied via individual inhaler wick for inhalation during a 15- minute experimental session.

  • OtherPeppermint essential oil

    Peppermint essential oil (Mentha piperita) administered by inhalation. Six drops are applied via inhaler wick for inhalation during a 15-minute experimental session.

  • OtherLavandula angustifolia and Mentha Piperita

    A combination of lavander (Lavandula angustifolia) and peppermint (Mentha piperita) essential oils administered by inhalation. Three drops of each administered via inhaler wick for inhalation during 15-minute experimental session.

  • OtherCoconut oil

    A placebo control solution consisting of coconut oil and distilled water adminstered by inhalation. Six drops of the mixture during a 15-minute experimental session.

06

What researchers measure

Primary outcomes

  1. Pain pressure threshold

    Pain pressure threshold mensured using a digital algometer at standardized craniofacial sites (masseter, temporalis, frontal, occipital and vertex) before and after inhalation of essential oils.

    Time frame: Baseline (pre- inhalation) and immediately after inhalation (within 15 minutes)

Secondary outcomes

  1. Hedonic perception of the aroma

    Immediately after inhalatioan (within 30 minutes)

    Time frame: Participants will report the perceveid pleasantness of inhaled aroma using standardized 9- point hedonic scale ranging from "extremely unpleasant" to "extremely pleasant"

07

Study locations

1 site
  • Intitute of Psychiatry- Hospital das Clínicas, University of São Paulo
    São Paulo, São Paulo 11, Brazil
08

References and documents

Individual participant data

Plan to share: Yes — Non-identifiable and non-sensitive individual participant data will be shared for academic and scientific purposes. The data will be available after the study is completed, for an indefinite period, through a virtual platform. The following will be shared: study design, statistical analysis plan, and consolidated research results. Access will be granted to interested researchers upon formal request, exclusively for secondary analyses, systematic reviews, or meta-analyses, with a commitment to ethical and academic use.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: The data will be available after the study is completed

Access criteria: Access will be granted to interested researchers upon formal request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 24 months is above that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Mar 25, 2026
StartActual
Mar 13, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07493434
Responsible party
Vanda de Lelis (Specialist in orofacial pain, University of Sao Paulo) — Principal investigator
First posted
Mar 25, 2026
Start date
Mar 13, 2025
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Mar 25, 2026

Study contacts

Mario F Peres, MD, PhD
principal investigator · University of Sao Paulo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion